Moreover, PPARα agonist treatment has been reported to improve pancreatic β-cell function in insulin-resistant rodents and the adaptive response of the pancreatic β-cell function to pathological conditions, such as obesity [51, 52]. Here, PPARA is linked to obesity disorder.